Asset Details
Do you wish to reserve the book?
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone
Do you wish to request the book?
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone
2013
Overview
Purpose
Netupitant is a new highly selective neurokinin-1 receptor antagonist being studied for the prevention of nausea and vomiting in patients undergoing chemotherapy. In vitro studies suggest that netupitant inhibits the cytochrome P-450 isoenzyme 3A4 (CYP3A4). Because netupitant may be used with a variety of drugs, which may be substrates of CYP3A4, two studies were designed to establish the potential risk for drug–drug interaction with three different CYP3A4 substrates: midazolam, erythromycin, and dexamethasone.
Methods
Both trials were three-period crossover studies performed in healthy subjects. In the first study, 20 subjects received netupitant and either midazolam or erythromycin. In the second study, 25 subjects received netupitant and dexamethasone. Serial blood samples were collected over the course of the two studies and pharmacokinetic parameters were determined for all analytes.
Results
Netupitant, by inhibiting the CYP3A4, increased the
C
max
and AUC
inf
of midazolam by 40 and 144 %, respectively, and the
C
max
and AUC
inf
of erythromycin by 30 %. Netupitant was shown to increase the exposure to dexamethasone in a dose-dependent manner with the mean increase in AUC and
C
max
by 72 and 11 %, respectively, on day 1 and by 138 and 75 %, respectively, on day 4 when co-administered with 300 mg of netupitant.
Conclusions
The results of these studies suggest that netupitant is a moderate inhibitor of CYP3A4 and therefore, co-administration with drugs that are substrates of CYP3A4 may require dose adjustments. Treatments were well tolerated in both studies.
Publisher
Springer Berlin Heidelberg
Subject
/ Cytochrome P-450 CYP3A Inhibitors
/ Dexamethasone - pharmacokinetics
/ Dexamethasone - pharmacology
/ Drug Administration Schedule
/ Erythromycin - pharmacokinetics
/ Humans
/ Male
/ Medicine
/ Midazolam - pharmacokinetics
/ Neurokinin-1 Receptor Antagonists - blood
/ Neurokinin-1 Receptor Antagonists - pharmacology
/ Nursing
/ Oncology
